Pfizer B7471014
Started: 11/2020
Study Name: A phase 3, single-arm trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy children 15 months through 17 years of age
Indication: Pneumococcal
Principal Investigators: Luke Anschutz, Dave Meduna
COVID-19 and Flu Swab Test Study Contact our Research Coordinator to ask
Phase III Study of live-attenuated respiratory syncytial virus (RSV) vaccine in healthy
Measles, mumps, rubella, varicella vaccine compared with ProQuad, administered in healthy children
24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Health Infants Given 4 Doses at
